Sanofi-aventis announced that it has completed the previously announced acquisition of BMP Sunstone Corporation.  At a special meeting of stockholders held on February 24, BMP Sunstone stockholders approved the adoption of the merger agreement among BMP Sunstone, sanofi-aventis and Star 2010, Inc., a wholly owned subsidiary of sanofi-aventis, dated October 28, 2010, as amended on November 22, 2010.  Following the special meeting, the merger was completed.

Pursuant to the merger agreement, BMP Sunstone stockholders will receive USD 10.00 per share in cash for each share of common stock they owned immediately prior to the effective time of the merger.  Stockholders of record will receive a letter of transmittal and instructions on how to surrender their shares of BMP Sunstone common stock to the paying agent in exchange for the merger consideration.

With the closing of the merger, BMP Sunstone common stock will no longer trade on the NASDAQ Global Market following today’s market close and will be delisted.   

Morgan, Lewis & Bockius LLP served as counsel to BMP Sunstone.  Stephens Inc. acted as financial advisor to BMP Sunstone.  Shearman & Sterling LLP served as counsel to sanofi-aventis.  Morgan Stanley acted as financial advisor to sanofi-aventis.

BMP Sunstone Corporation is a specialty pharmaceutical company that is building a proprietary portfolio of branded pharmaceutical and healthcare products in China. Through Sunstone the company manufactures leading pediatric and women's health products sold in pharmacies throughout the country.

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone.